UK Peptides · Research Index

Every Research & Regulatory News Question Answered, in 55 Studies

Trial readouts, regulatory decisions and enforcement affecting peptide research in the UK.

55 referenced articles

Open research questions

  • Is orforglipron a peptide?
  • Has retatrutide been approved by the MHRA?
  • What did TRIUMPH-1 actually report?
  • Why can orforglipron be taken as a tablet when peptides cannot?
  • Are research peptides legal in the UK?
  • What is the difference between MHRA authorisation and NHS availability?

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Handling checklist

  • Check the compound named in a trial registration matches the compound being discussed
  • Confirm the NCT identifier resolves to the acronym being cited
  • Read topline press releases as preliminary until peer-reviewed publication
  • Separate the trial population from the headline percentage before comparing studies
  • Treat authorisation in one jurisdiction as saying nothing about status in another

Common mistakes

Treating a positive Phase 3 as approval
Filing begins a review that commonly takes a year or more and can end in a request for more data.
Comparing weight-reduction percentages across different trials
Population, duration and comparator differ; the numbers are not interchangeable.
Assuming one incretin's approval legitimises another compound
Authorisations are product-specific and do not transfer between compounds.
Citing a TRIUMPH number without checking the NCT identifier
Verify against ClinicalTrials.gov — the numbering has been widely misreported.
Reading research material as an alternative to a licensed medicine
Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Related reading

Reference material for laboratory research. Not medical advice, and not an offer to supply any compound for human use.